Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE: OPK), has surpassed 50% enrollment in the first phase 3 trial of RayaldyTM to treat patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. This trial is the first of two identical randomized, double-blind, placebo controlled, multi-site studies intended to establish the safety and efficacy of RayaldyTM as a new treatment for SHPT in the targeted population. The endpoints of both studies, which will be conducted in parallel, include vitamin D status and changes in serum calcium, serum phosphorus and plasma intact parathyroid hormone (PTH).
Help employers find you! Check out all the jobs and post your resume.
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE: OPK), has surpassed 50% enrollment in the first phase 3 trial of RayaldyTM to treat patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. This trial is the first of two identical randomized, double-blind, placebo controlled, multi-site studies intended to establish the safety and efficacy of RayaldyTM as a new treatment for SHPT in the targeted population. The endpoints of both studies, which will be conducted in parallel, include vitamin D status and changes in serum calcium, serum phosphorus and plasma intact parathyroid hormone (PTH).
Help employers find you! Check out all the jobs and post your resume.
